ELV - Educational Analysis * US Equities
Educational Analysis * US Equities

ELV

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerELV
CategoryEducational primer
Last reviewedNovember 9, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Elevance Health sits inside the Healthcare sector, specifically the Medical - Healthcare Plans industry. It is one of the largest U.S. health insurers by medical membership, serving approximately 45.2 million medical members through affiliated health plans as of December 31, 2025. It operates as an independent Blue Cross and Blue Shield Association licensee in 14 states/territories under Anthem Blue Cross and Anthem Blue Cross and Blue Shield brands. Revenue flows from risk-based premiums, administrative fees for self-funded employers, and pharmacy/health service fees through its Carelon businesses. The company reports through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other.

On the numbers, the ROE sits at 11.6% with a net margin of 2.5%. That margin level is characteristic of a business whose top line is huge premium revenue consumed mostly by claims and medical costs, leaving only a slim residual for shareholders. An 11.6% ROE suggests modest financial leverage and scale efficiency — not a wide-moat consumer franchise, but enough scale that the company can still generate a reasonable return on equity despite razor-thin underwriting profitability. Scale and regulatory licensing relationships with the Blue Cross and Blue Shield system give it some competitive insulation, while the 2.5% net margin confirms pricing power is heavily regulated and constrained by medical-loss-ratio rules.

Financial posture

At the time of the data snapshot, Elevance Health carries a market cap of $91.1 billion, trades at a P/E of 18.0, and has a beta of 0.71. The 18.0 P/E sits in a zone typical for large-cap managed-care organizations: not cheap, but not aggressively valued, either. The sub-1.0 beta aligns with the historical perception of healthcare plans as defensive, less economically sensitive holdings.

The profitability profile is mixed. Net margin of 2.5% is thin, yet ROE of 11.6% shows the company can still compound shareholder capital profitably. That gap between margin and ROE usually points to balance-sheet leverage and high asset turnover — convert massive premium payments into net income quickly. Investors should not expect software-like margins, but they should note whether the company can defend ROE as interest rates and medical costs fluctuate.

Strategic priorities & outlook

Elevance Health's most recent 10-K filing outlines four near-term operational priorities. First, the company wants to keep pushing value-based payment models so that reimbursement is tied to care quality and setting rather than pure volume. Second, it intends to rationalize its portfolio and align investment toward core businesses and higher-growth capabilities. Third, it is focused on technology upgrades to improve interactions with customers, providers, brokers, agents and employees — covering distribution, service, clinical coordination and administrative efficiency. Fourth, it aims to maintain market-competitive value while achieving appropriate profitability across customer segments.

One operational fact worth filing away: U.S. government agencies accounted for approximately 32% of total consolidated revenues in 2025, with most of that concentrated in the Health Benefits segment. That government exposure is a double-edged theme — it provides scale and membership stability, especially in Medicaid and Medicare, but it also ties a large share of revenue to federal and state funding decisions, reimbursement rules, and policy shifts.

Macro & geopolitical exposure

As a managed-care and health-plan business, Elevance Health is structurally exposed to U.S. healthcare regulation and reimbursement policy. The government-funded portion of its revenue — around 32% in 2025 — means federal Medicare funding levels, state Medicaid budgets, and Affordable Care Act rulemaking all flow through to its top line. Political shifts in Washington can therefore alter reimbursement rates, eligibility requirements and competitive dynamics without warning.

Currency and direct overseas commodity exposure are minor here: this is a domestic U.S. story. The bigger macro risks are medical-cost inflation, labor shortages in care delivery that push unit costs higher, prescription-drug pricing legislation, and antitrust scrutiny of vertical integration between insurers and pharmacy benefits managers. Interest rates matter too, because insurers hold large investment portfolios and because financing conditions can influence acquisition-driven growth.

Recent developments

Recent news coverage has been relatively constructive for ELV. On November 4, 2026, a 247wallst.com headline noted CVS tumbled 12% on plans to split into two companies despite an earnings beat, while Elevance Health rose 4% and Cigna climbed 3% — suggesting peer volatility created sector-wide repricing rather than company-specific optimism for Elevance. Earlier, on October 30, 2026, zacks.com flagged that ELV was up 2.73% in one week. On October 27, 2026, gurufocus.com published a DCF-based "Fairly Valued" call at $418, and defenseworld.net reported that Citizens Financial Group's RI unit had added ELV stock. The $418 fair-value estimate and the $421.75 current price put the stock right near that DCF-implied intrinsic value, which means the market has already discounted a lot of expected earnings power.

Earnings behavior & post-earnings drift

Elevance Health has recorded a strong beat rate over the last eight reported quarters, coming in ahead of estimates in seven of the eight, or 88% of the time, with an average EPS surprise of 15%. The average 5-day price move following those reports is 2.38% to the upside.

Still, the real lesson for traders is that beats do not guarantee directional follow-through. The most recent report on October 21, 2026 delivered a 48.4% EPS beat — actual EPS of $6.99 against an estimate of $4.71 — yet the next-day move was only 2.57%, and the stock drifted -4.54% over the following five sessions. The same pattern appeared on July 15, 2026: a 20.0% beat produced a -4.48% next-day drop and essentially flat five-day drift (-0.32%). The strongest post-earnings run came from April 22, 2026, when a 16.3% beat was followed by a 5.51% next-day pop and a 14.76% five-day rally. The January 28, 2026 report, a 7.4% beat, delivered a 1.5% next-day move and a -0.37% five-day drift.

This inconsistency is the key takeaway. The unofficial consensus tends to look more at guidance, medical-cost commentary, and government-program momentum than at the EPS beat itself. With the next report scheduled for January 27, 2027 before the open and the current consensus EPS estimate at $2.08, anyone watching the name should treat the release as a catalyst for guidance commentary rather than a simple buy-the-beat setup.

For a deeper dive into how institutional analysts currently weigh these factors, look at the full institutional verdict on ELV.

Frequently Asked Questions

What does Elevance Health actually do?

Elevance Health is a large U.S. managed-care company serving about 45.2 million medical members through affiliated health plans. It offers risk-based and fee-based health benefit plans to individual, employer, Medicaid and Medicare markets, plus pharmacy and healthcare services through its Carelon segments.

How reliable has Elevance Health been at beating earnings estimates?

Over the last eight reported quarters, Elevance Health beat estimates seven times, an 88% beat rate, with an average EPS surprise of 15%. However, the stock's post-earnings price reaction has been inconsistent.

What is Elevance Health's next earnings date and consensus estimate?

The next scheduled earnings report is January 27, 2027 before the market open, with a current consensus EPS estimate of $2.08.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 9, 2026
Elevance Health Inc. · Healthcare / Medical - Healthcare Plans
$91.1BMarket cap
18.0P/E
2.5%Net margin
11.6%ROE
88%Beat rate, last 8Q
15%Avg EPS surprise
2.38%Avg 5-day move after earnings
2027-01-27Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-10-21$6.99$4.71+48.4%+2.57%-4.54%
2026-07-15$7.45$6.21+20%-4.48%-0.32%
2026-04-22$12.58$10.82+16.3%+5.51%+14.76%
2026-01-28$3.33$3.1+7.4%+1.5%-0.37%
2025-10-21$6.03$4.93+22.3%--
2025-07-17$8.84$8.91-0.8%--

Previous ELV editions

Beyond the primer

Get the institutional verdict on ELV

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the ELV verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.